Monoclonal antibody production service: scale, purity and documentation

Matching a monoclonal antibody service to the purpose

1. Transient expression for speed and small scale. Transfecting cells for a short production run gives material in weeks without developing a line. It suits research quantities, candidate comparison and early studies, and the cost per unit rises steeply as quantity grows.
2. Stable line for quantity and repeatability. Developing a stable line costs months and pays back at scale and where every batch must match. Programmes that will need material repeatedly should start the line early, because it sits on the critical path of everything that follows.
3. Purification depth follows the use. Affinity capture alone suits many research uses. Polishing to remove aggregate, and additional steps to remove host cell protein and DNA, are needed where the material goes into cells, into animals or toward a regulated application. Each step costs yield as well as money.
4. Endotoxin, aggregate and the formulation. Specify an endotoxin limit for anything touching cells or animals, an aggregate limit, and the final buffer and concentration. Antibody delivered in the provider's default formulation frequently needs an exchange the customer then performs badly.
5. Documentation matched to the destination. Research material needs a certificate of analysis. Material heading toward a regulated application needs manufacturing records, a traceable cell bank and a quality system, and retrofitting those onto a research batch is not possible.

What a monoclonal antibodies manufacturer or one of the monoclonal antibody companies should send with each batch

Identity confirmation, concentration by a stated method, purity with the method and the trace, aggregate content, endotoxin where relevant, and the cell bank and process reference. Ask for the traces rather than a summary certificate.

Retain an aliquot of each batch under your own control. Without a retained reference, a question about whether a new batch differs cannot be answered.

Mouse monoclonal antibody or a rabbit monoclonal antibody service: species, isotype and compatibility

The host species and isotype determine which secondary reagents and which purification chemistry apply, and they can constrain multiplexing later. Fix them from the intended applications rather than from what the provider produces most easily.

Where the antibody may be humanised or engineered later, having the variable region sequences in hand makes that a straightforward project instead of a repeat of the discovery work.

A fully human generated monoclonal antibody, and the routes to one

Three routes give a fully human antibody. Transgenic animals carrying human immunoglobulin loci are immunised and their B cells screened, which yields affinity-matured antibodies with human sequence. Display libraries, phage or yeast, select from human repertoires in vitro, which allows selection against difficult antigens under controlled conditions and needs affinity maturation afterwards. Single B cell cloning from immune human donors recovers a natural pairing directly. Each brings its own licensing position, which is a commercial rather than a scientific consideration and is worth settling before a campaign.

Common questions

Transient or stable expression for monoclonal antibodies production?

Transient for speed and research quantities, since it needs no line development. Stable for larger quantities and batch-to-batch consistency, accepting several months of development first.

How pure does the antibody need to be?

Affinity capture alone suits many research uses. Cell-based work, animal work and anything heading toward a regulated application need polishing and host cell protein and DNA removal, each costing yield.

What should antibody services show on a certificate of analysis?

Identity, concentration and purity each by a stated method with the trace, aggregate content, and endotoxin where the material touches cells or animals, against limits agreed before manufacture.

Can research material be used later for a regulated application?

Generally not. Regulated use requires manufacturing records, a traceable cell bank and a quality system that cannot be applied retrospectively to a research batch.

Browse by service class

• Compare Gene synthesis on advertised prices